Conventional
( DrugBank: - / KEGG DRUG: - )
1 disease
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
63 | Idiopathic thrombocytopenic purpura | 5 |
63. Idiopathic thrombocytopenic purpura
Clinical trials : 391 / Drugs : 235 - (DrugBank : 50) / Drug target genes : 49 - Drug target pathways : 139
Showing 1 to 5 of 5 trials
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03412188 (ClinicalTrials.gov) | August 1, 201820180801 | 20/1/201820180120 | The Effect of Eltrombopag on the Expression of Platelet Collagen Receptor GPVI in Pediatric ITP. | Evaluation of the Effect of Eltrombopag on the Expression of Platelet Collagen Receptor Glycoprotein VI (GPVI) in Pediatric Patients With Chronic and Persistent Immune Thrombocytopenia. Evaluation of the Effect of Eltrombopag on the Expression of Platelet Collagen Receptor Glycoprotein ... | Idiopathic Thrombocytopenic Purpura | Drug: Eltrombopag;Drug: conventional | Nayera Hazaa Elsherif | NULL | Completed | 1 Year | 18 Years | All | 36 | N/A | Egypt |
2 | ChiCTR-ONC-17013230 | 2017-05-2020170520 | 2017-11-0320171103 | A single center, one-arm, and open clinical study of PKA agonist (aminophylline) with conventional treatment for chronic or refractory primary immune thrombocytopenia A single center, one-arm, and open clinical study of PKA agonist (aminophylline) with conventionaltr ... | A single center, one-arm, and open clinical study of PKA agonist (aminophylline) with conventional treatment for chronic or refractory primary immune thrombocytopenia A single center, one-arm, and open clinical study of PKA agonist (aminophylline) with conventionaltr ... | primary immune thrombocytopenia | Case series:PKA agonist (aminophylline) treats chronic or refractory primary immune thrombocytopenia; Case series:PKA agonist (aminophylline) treats chronic or refractory primary immune thrombocytopenia ... | Department of Hematology, The First Affiliated Hospital of Soochow University | NULL | Completed | 11 | 65 | Both | Case series:60; | China | |
3 | ChiCTR-IIR-16008994 | 2016-09-0120160901 | 2016-08-0820160808 | Safety and efficacy analysis of two conventional dosage regimens Methylprednisone for initial treatment of primary immune thrombocytopenia:A multicenter randomized controlled clinical trial Safety and efficacy analysis of two conventionaldosage regimens Methylprednisone for initial treatme ... | Safety and efficacy analysis of two conventional dosage regimens Methylprednisone for initial treatment of primary immune thrombocytopenia:A multicenter randomized controlled clinical trial Safety and efficacy analysis of two conventionaldosage regimens Methylprednisone for initial treatme ... | Primary immune thrombocytopenia | the short-course group (Group A):Oral methylprednisolone for 2 weeks, the initial dosage is 0.8mg/kg/d, than reduces to 0.4mg/kg/d for 1 week, than to 0.2mg/kg/d for 1 week, than stop.;the long-course treatment group (Group B):Oral methylprednisolone for 1 month, the initial dosage is 0.8mg/kg/d,than reduces to 0.4mg/kg/d for 1 month, than to 0.1mg/kg/d for 2 week, than stop.; the short-course group (Group A):Oral methylprednisolone for 2 weeks, the initial dosage is 0.8mg/kg ... | Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union ... | NULL | Pending | 18 | 60 | Both | the short-course group (Group A):150;the long-course treatment group (Group B):150; | 4 (Phase 4 study) | China |
4 | NCT01356511 (ClinicalTrials.gov) | September 201020100900 | 17/5/201120110517 | High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) High-dose Dexamethasone Versus ConventionalDose Prednisone for Initial Treatment of Primary Immune T ... | High-dose Dexamethasone and Conventional Dose Prednisone, for the First-line Treatment of Adults With ITP: a Multicenter, Randomized Controlled, Clinical Trial High-dose Dexamethasone and ConventionalDose Prednisone, for the First-line Treatment of Adults With ... | Purpura, Thrombocytopenic, Idiopathic | Drug: Prednisone;Drug: Dexamethasone | Shandong University | Chinese Academy of Medical Sciences;Peking Union Medical College Hospital;Ruijin Hospital;Wuhan Union Hospital, China;Tongji Hospital;Shandong University of Traditional Chinese Medicine;Anhui Provincial Hospital;Zhejiang Provincial Hospital of TCM;Second Hospital of Shanxi Medical University;Xinjiang Uygur Autonomous Region People's Hospital;Shenzhen Second People's Hospital Chinese Academy of Medical Sciences;Peking Union Medical College Hospital;Ruijin Hospital;Wuhan Unio ... | Completed | 18 Years | 80 Years | Both | 261 | Phase 4 | China |
5 | NCT00451594 (ClinicalTrials.gov) | September 200520050900 | 22/3/200720070322 | High Dose Dexamethasone Vs. Conventional Dose Prednisolone in Adult ITP | A Randomized Controlled Multicentre Trial of High Dose Dexamethasone Versus Conventional Dose Prednisolone for Adults With Untreated Idiopathic Thrombocytopenic Purpura A Randomized Controlled Multicentre Trial of High Dose Dexamethasone Versus ConventionalDose Prednis ... | Idiopathic Thrombocytopenic Purpura | Drug: Dexamethasone;Drug: Prednisolone | Cooperative Study Group A for Hematology | NULL | Completed | 16 Years | N/A | Both | 157 | Phase 3 | Korea, Republic of |